Search Results - "Aplin, Andrew E"

Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation by Rogers, Corey, Erkes, Dan A., Nardone, Alexandria, Aplin, Andrew E., Fernandes-Alnemri, Teresa, Alnemri, Emad S.

“…Gasdermin E (GSDME/DFNA5) cleavage by caspase-3 liberates the GSDME-N domain, which mediates pyroptosis by forming pores in the plasma membrane. Here we show…”
Get full text

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment by Teh, Jessica L F, Aplin, Andrew E

“…The uncontrolled proliferation of cancer cells has led to the development of small-molecule inhibitors to target cell-cycle progression. Palbociclib,…”
Get full text

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis by Erkes, Dan A, Cai, Weijia, Sanchez, Ileine M, Purwin, Timothy J, Rogers, Corey, Field, Conroy O, Berger, Adam C, Hartsough, Edward J, Rodeck, Ulrich, Alnemri, Emad S, Aplin, Andrew E

“…Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat -mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer…”
Get more information

Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells by YONGPING SHAO, APLIN, Andrew E

“…Melanoma cells are highly resistant to anoikis, a form of apoptosis induced in nonadherent/inappropriate adhesion conditions. Depleting B-RAF or the…”
Get full text

Roles of the BAP1 Tumor Suppressor in Cell Metabolism by Han, Anna, Purwin, Timothy J, Aplin, Andrew E

“…BRCA1-associated protein 1 ( ) is emerging as an intensively studied cancer-associated gene. Germline mutations in lead to a cancer syndrome, and somatic loss…”
Get full text

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma by Vu, Ha Linh, Aplin, Andrew E

“…Melanoma is a devastating form of skin cancer with limited therapeutic options. Fifteen to 20% of patients with melanoma have an activating mutation in the…”
Get full text

Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway by Li, Xiang, Wang, Shaomin, Mu, Wei, Barry, Jennifer, Han, Anna, Carpenter, Richard L, Jiang, Bing-Hua, Peiper, Stephen C, Mahoney, Mỹ G, Aplin, Andrew E, Ren, Hong, He, Jun

“…Cancer cells have an imbalance in oxidation-reduction (redox) homeostasis. Understanding the precise mechanisms and the impact of the altered redox…”
Get full text

RAS-mediated tumor stress adaptation and the targeting opportunities it presents by Redding, Alexandra, Aplin, Andrew E, Grabocka, Elda

“…Cellular stress is known to function in synergistic cooperation with oncogenic mutations during tumorigenesis to drive cancer progression. Oncogenic RAS is a…”
Get full text

Raptinal Induces Gasdermin E-Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma by Vernon, Megane, Wilski, Nicole A, Kotas, Daniel, Cai, Weijia, Pomante, Danielle, Tiago, Manoela, Alnemri, Emad S, Aplin, Andrew E

“…Lack of response and acquired resistance continue to be limitations of targeted and immune-based therapies. Pyroptosis is an inflammatory form of cell death…”
Get full text

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma by Cai, Weijia, Nguyen, Mai Q, Wilski, Nicole A, Purwin, Timothy J, Vernon, Mégane, Tiago, Manoela, Aplin, Andrew E

“…Melanomas frequently harbor activating NRAS mutations. However, limited advance has been made in developing targeted therapy options for patients with NRAS…”
Get full text

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma by Capparelli, Claudia, Purwin, Timothy J., Glasheen, McKenna, Caksa, Signe, Tiago, Manoela, Wilski, Nicole, Pomante, Danielle, Rosenbaum, Sheera, Nguyen, Mai Q., Cai, Weijia, Franco-Barraza, Janusz, Zheng, Richard, Kumar, Gaurav, Chervoneva, Inna, Shimada, Ayako, Rebecca, Vito W., Snook, Adam E., Hookim, Kim, Xu, Xiaowei, Cukierman, Edna, Herlyn, Meenhard, Aplin, Andrew E.

“…Cellular plasticity contributes to intra-tumoral heterogeneity and phenotype switching, which enable adaptation to metastatic microenvironments and resistance…”
Get full text

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma by Cheng, Hanyin, Terai, Mizue, Kageyama, Ken, Ozaki, Shinji, McCue, Peter A, Sato, Takami, Aplin, Andrew E

“…Uveal melanoma patients with metastatic disease usually die within one year, emphasizing an urgent need to develop new treatment strategies for this cancer…”
Get full text

Lysosomal lipid peroxidation regulates tumor immunity by Bhardwaj, Monika, Lee, Jennifer J, Versace, Amanda M, Harper, Sandra L, Goldman, Aaron R, Crissey, Mary Ann S, Jain, Vaibhav, Singh, Mahendra Pal, Vernon, Megane, Aplin, Andrew E, Lee, Seokwoo, Morita, Masao, Winkler, Jeffrey D, Liu, Qin, Speicher, David W, Amaravadi, Ravi K

“…Lysosomal inhibition elicited by palmitoyl-protein thioesterase 1 (PPT1) inhibitors such as DC661 can produce cell death, but the mechanism for this is not…”
Get full text

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association by Vido, Michael J., Le, Kaitlyn, Hartsough, Edward J., Aplin, Andrew E.

“…Expression of aberrantly spliced BRAF V600E isoforms (BRAF V600E ΔEx) mediates resistance in 13%–30% of melanoma patients progressing on RAF inhibitors. BRAF…”
Get full text

FOXD3 Regulates VISTA Expression in Melanoma by Rosenbaum, Sheera R., Knecht, Meghan, Mollaee, Mehri, Zhong, Zhijiu, Erkes, Dan A., McCue, Peter A., Chervoneva, Inna, Berger, Adam C., Lo, Jennifer A., Fisher, David E., Gershenwald, Jeffrey E., Davies, Michael A., Purwin, Timothy J., Aplin, Andrew E.

“…Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of…”
Get full text

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma by Han, Shujun, Ren, Yibo, He, Wangxiao, Liu, Huadong, Zhi, Zhe, Zhu, Xinliang, Yang, Tielin, Rong, Yu, Ma, Bohan, Purwin, Timothy J., Ouyang, Zhenlin, Li, Caixia, Wang, Xun, Wang, Xueqiang, Yang, Huizi, Zheng, Yan, Aplin, Andrew E., Liu, Jiankang, Shao, Yongping

“…In human mutant BRAF melanoma cells, the stemness transcription factor FOXD3 is rapidly induced by inhibition of ERK1/2 signaling and mediates adaptive…”
Get full text

Adaptive resistance to RAF inhibitors in melanoma by Kugel III, Curtis H., Aplin, Andrew E.

“…Summary The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the door to new treatment options, which have resulted in…”
Get full text

RAC1 P29S regulates PD-L1 expression in melanoma by Vu, Ha Linh, Rosenbaum, Sheera, Purwin, Timothy J., Davies, Michael A., Aplin, Andrew E.

“…Summary Whole exome sequencing of cutaneous melanoma has led to the detection of P29 mutations in RAC1 in 5–9% of samples, but the role of RAC1 P29 mutations…”
Get full text

Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023 by Seedor, Rino S, Aplin, Andrew E, Bertolotto, Corine, Carvajal, Richard D, Deacon, Nigel, Doble, Katie, Hamid, Omid, Haq, Rizwan, Kadosh, Miriam, Khan, Shaheer, Kraska, Jacqueline, Lutzky, Jose, McKean, Meredith, Montazeri, Kamaneh, Moser, Justin, Onken, Michael, Orloff, Marlana, Sacco, Joseph J, Smalley, Keiran, Selig, Sara M

“…The 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting was held in Philadelphia on November 6, 2023. There is increased awareness and dedicated…”
Get full text

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma by Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie

“…Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of…”
Get full text